Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold
Gabriel Bsteh,Harald Hegen,Nik Krajnc,Fabian Föttinger,Patrick Altmann,Michael Auer,Klaus Berek,Barbara Kornek,Fritz Leutmezer,Stefan Macher,Tobias Monschein,Markus Ponleitner,Paulus Rommer,Christiane Schmied,Karin Zebenholzer,Gudrun Zulehner,Tobias Zrzavy,Florian Deisenhammer,Franziska Di Pauli,Berthold Pemp,Thomas Berger
DOI: https://doi.org/10.1002/acn3.52279
IF: 5.43
2024-12-18
Annals of Clinical and Translational Neurology
Abstract:Objective To investigate retinal layer thinning as a biomarker of disease‐modifying treatment (DMT) effects in relapsing multiple sclerosis (RMS). Methods From an ongoing prospective observational study, we included patients with RMS, who (i) had an optical coherence tomography (OCT) scan within 6 to 12 months after DMT start (rebaseline) and ≥1 follow‐up OCT ≥12 months after rebaseline and (ii) adhered to DMT during follow‐up. Differences between DMT in thinning of peripapillary‐retinal‐nerve‐fiber‐layer (pRNFL) and macular ganglion cell‐plus‐inner plexiform‐layer (GCIPL) were analyzed using mixed‐effects linear regression. Eyes suffering optic neuritis during follow‐up were excluded. Results We included 291 RMS patients (mean age 30.8 years [SD 7.9], 72.9% female, median disease duration 9 months [range 6–94], median rebaseline‐to‐last‐follow‐up‐interval 32 months [12–82]). Mean annualized rates of retinal layer thinning (%/year) in reference to DMF (n = 84, GCIPL 0.28, pRNFL 0.53) were similar under TERI (n = 18, GCIPL 0.34, pRNFL 0.59), GLAT (n = 24, GCIPL 0.32, pRNFL 0.56), and IFNb (n = 13, GCIPL 0.33, pRNFL 0.60) were slightly lower under S1PM (n = 27, GCIPL 0.19, pRNFL 0.42) and CLA (n = 23, GCIPL 0.20, pRNFL 0.42), and were significantly lower under NTZ (n = 47, GCIPL 0.09, pRNFL 0.24; both p
neurosciences,clinical neurology